Leaflet TRAZEC 180mg film-coated tablets


Indicated for: type 2 diabetes mellitus

Route of administration: oral

Substance: nateglinide (antidiabetic)

ATC: A10BX03 (Alimentary tract and metabolism | Blood glucose lowering drugs, excl. insulins | Other blood glucose lowering drugs, excl. insulins)

Nateglinide is an antidiabetic medication used to control blood sugar levels in patients with type 2 diabetes. It belongs to the meglitinide class and works by stimulating insulin secretion from the pancreas, particularly after meals.

The medication is taken orally, usually before meals, with the dose adjusted based on blood glucose levels. Common side effects include hypoglycemia, nausea, and weight gain.

Nateglinide is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or hypersensitivity to the active substance. It should also be used with caution in patients with hepatic or renal impairment.

This medication is an effective option for controlling postprandial blood sugar levels, helping to prevent complications associated with type 2 diabetes.

General data about TRAZEC 180mg

  • Substance: nateglinide
  • Date of last drug list: 01-07-2013
  • Commercial code: W51759005
  • Concentration: 180mg
  • Pharmaceutical form: film-coated tablets
  • Quantity: 360
  • Product type: original
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Concentrations available for nateglinide

  • 120mg
  • 180mg
  • 60mg